INOVOTION’s highly-relevant next-generation in vivo model evaluates the efficacy of immunotherapy treatments and combinations.
Researchers consistently rely on INOVOTION to secure their developments on ADCs, antibodies, bi-specifics, ADCCs, checkpoint inhibitors and combinations.
With 2 specific tracks focusing on immuno-oncology, WPC Europe is a key opportunity to learn about INOVOTION’s latest innovative results.